Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
PHASE1
To investigate safety, tolerability, PK and PD of BI 655075 and to establis...
Status
Completed
Location
1321.2.1 Boehringer Ingelheim Investigational Site
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects
PHASE1
The primary objective is to investigate the safety, tolerability and pharma...
Status
Completed
Location
1321.5.00001 Boehringer Ingelheim Investigational Site